Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $21,577.40 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider Lorenz Muller sold 11,180 shares of Milestone Pharmaceuticals stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a total value of $21,577.40. Following the completion of the transaction, the insider directly owned 205,406 shares of the company’s stock, valued at $396,433.58. This represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Lorenz Muller also recently made the following trade(s):

• On Monday, December 15th, Lorenz Muller sold 53,566 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.32, for a total value of $124,273.12.

Milestone Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ MIST opened at $1.91 on Friday. The stock has a market capitalization of $162.67 million, a P/E ratio of -2.33 and a beta of 0.44. The stock’s fifty day moving average is $2.22 and its 200 day moving average is $1.97. Milestone Pharmaceuticals Inc. has a 52 week low of $0.63 and a 52 week high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Sell-side analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Finally, Zacks Research raised Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Large investors have recently bought and sold shares of the company. Creative Planning boosted its stake in shares of Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares in the last quarter. Raymond James Financial Inc. boosted its position in Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after buying an additional 10,000 shares during the period. Bay Rivers Group grew its holdings in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after acquiring an additional 12,170 shares during the last quarter. Sapient Capital LLC bought a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $25,000. Finally, Bank of America Corp DE increased its position in Milestone Pharmaceuticals by 200,550.0% in the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after acquiring an additional 16,044 shares during the period. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.